Viome Raises $25 Million in Funding to Revolutionize Personalized Healthcare Testing

Viome Life Sciences, Inc., a pioneering force in the health technology landscape, has successfully raised an impressive $25 million in funding to accelerate its mission of transforming healthcare. At the forefront of direct-to-consumer testing, Viome utilizes proprietary technology licensed from the prestigious Los Alamos National Laboratory. This groundbreaking platform analyzes both microbial and human gene expressions (mRNA) to deliver unparalleled health insights tailored specifically to each individual’s unique biochemistry. The recent funding will be instrumental in expanding Viome’s innovative product offerings, refining its data analysis capabilities, and enhancing the customer experience through technology. Viome is committed to empowering individuals with the knowledge they need to take control of their health—making illness a matter of choice rather than fate. By providing at-home tests that not only assess health at a single point but serve as an ongoing companion, Viome ensures that users receive personalized, actionable, and adaptive health recommendations over time. This funding round marks a significant milestone for a company driven by a passionate team of scientists, engineers, researchers, and entrepreneurs who are dedicated to pushing the boundaries of healthcare. As Viome continues to innovate and expand its reach, it stands on the cusp of redefining what it means to be proactive about health, aligning perfectly with its vision of achieving optimal wellness for all.